Matthew Gall
Chief Financial Officer · Tango Therapeutics, Inc.
- 2024
- May 5, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew Gall files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Adam Crystal - $6.99M in TNGX purchases and sales in the last 12 months
- Srinivas Akkaraju - $6.18M in KLRS purchases and sales in the last 12 months
- Third Rock Ventures IV, L.P. - $4.85M in TNGX purchases and sales in the last 12 months
- Barbara Weber - $374K in TNGX purchases and sales in the last 12 months
- Daniella Beckman - $127K in TNGX purchases and sales in the last 12 months
- Brett R. Hagen - $13K in KLRS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew Gall?
Matthew Gall is a corporate insider, tracked as Chief Financial Officer of Tango Therapeutics, Inc. (TNGX). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Matthew Gall last file a Form 4?
The most recent primary Form 4 on record is dated 5 May 2026, one of 5 filings going back to 2024.
Has Matthew Gall been buying or selling stock?
Recorded transactions: 1 open-market purchase ($39K) and 0 open-market sales across all tracked filings.
